Home
About Us
Our Technology
Our Pipeline
Patients
Investors & Media
Career
Contact Us
EN—CN

Our Pipeline

  • Program
  • Target
  • Indication
  • Discovery
  • POC / Pre-clinical
  • IND Phase I
  • IND Phase II/III
  • Development
Solid
Tumors
  • Ori-C101
  • GPC3
  • HCC / Solid tumor
  • Global
  • Ori-C101 GPC3 CAR-T

    for the treatment of advanced Hepatocellular Carcinoma

    The first CAR-T product developed by Oricell for the treatment of advanced hepatocellular carcinoma, has received positive data from its exploratory clinical study and was presented at ASCO 2021. The product is currently in its phase I clinical trial stage in collaboration with Zhongshan Hospital, Sir Run Run Shaw Hospital and West China Hospital of Sichuan University.

  • OriC902
  • Secreting CAR-T
  • HCC / Solid tumor
  • Oricell

  • OriC613
  • CLDN18.2 / MSLN
  • Gastric & Pancreatic Tumors
  • Global

Liquid
Tumors
  • OriCAR-017
  • GPRC5D
  • R/R MM
  • Global
  • OriCAR-017 GPRC5D target

    for the treatment of Relapsed / Refractory Multiple Myeloma

    OriCAR-017, China's first and the world's second CAR-T product targeting GPRC5D for the treatment of relapsed refractory multiple myeloma has received orphan drug designation from FDA and IND clearance from NMPA. Data from its exploratory clinical study were presented in oral presentations at the 2022 and ASCO Annual Meeting and the 2022 EHA Congress and 2024 ASH, and its follow-up data were published in The Lancet Haematology.

  • OriC322
  • MM (ND/RR)
  • GPRC5D/ BCMA
  • Global

InVivo
CAR-T
  • OriV118
  • GPRC5D/ BCMA
  • MM (ND/RR)
  • Partnered

  • Undisclosed
  • Undisclosed
  • Solid tumor
  • Oricell

We actively seek collaboration globally across R&D stages for our pipeline.

Swipe left and right to see more
  • About Multiple Myeloma (MM)

    Multiple myeloma (MM), one of the most common blood cancers, is a malignant disease of abnormal proliferation of clonal plasma cells. For newly treated MM patients, commonly used first-line treatment drugs include proteasome inhibitors, immunomodulatory drugs and alkylating agents. For most patients, the commonly used first-line treatments can stabilize the patient's condition for 3-5 years, but a small number of patients show primary drug resistance at initial treatment, and the disease cannot be effectively controlled. Most of the newly treated patients with effective treatment will inevitably enter the relapse and refractory stage after the stable disease period. Therefore, there is still an unmet clinical need for patients with relapsed/refractory multiple myeloma.

    Source：
    GLOBOCAN 2020 Global Cancer Statistics
    Frost & Sullivan Report

    176K

    New cases worldwide

    117K

    Deaths worldwide

    ~12bn

    CAR-T Market

  • About Hepatocellular Carcinoma (HCC)

    Hepatocellular Carcinoma is the sixth most common cancer in the world and the third in terms of causing death, after lung and colorectal cancers. According to statistics, in 2020, the number of new patients with liver cancer worldwide is 905,677 cases and the number of deaths is 830,180 cases, with the number of deaths being very close to the number of new cases. The latest statistics from China's National Cancer Center 2021 shows, in 2015, the number of Hepatocellular Carcinoma patients in China was 370,000, ranking 4th (lung, stomach, colorectal, liver), and the incidence rate ranked 5th (after lung cancer, breast cancer, gastric cancer and colorectal cancer). The number of deaths due to Hepatocellular Carcinoma was 326,000, with the number of deaths and mortality rate ranked 2nd (After lung cancer).
    According to China's National Health Commission's Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2022 edition), systemic antitumor therapy for patients with intermediate to advanced stage hepatocellular carcinoma mainly focuses on controlling the progression of the disease and prolonging the survival time of patients.
    In recent years, combinations of immune checkpoint inhibitor therapy with targeted drugs, chemotherapeutic agents, and local therapies has begun to be used for the second-line treatment of liver cancer, and new treatment methods are constantly being explored. The overall response rate is still low, and the typical ORR is not higher than 15%, the therapeutic options for intermediate to advanced stage HCC are still extremely limited, and there is an urgent clinical need for new and effective therapeutic methods.
    CAR-T immunotherapy has become the focus of attention in the field of cancer treatment around the world, and is expected to become the method with the highest valuable and potential outside of traditional means of treatment. CAR-T immune cell therapy has achieved breakthrough progress and good clinical therapeutic effects in hematological tumors, and has shown its initial efficacy in solid tumors.

    Source：
    GLOBOCAN 2020
    Hepatocellular Carcinoma Treatment Guidelines (2022 Edition)

    906K

    New cases worldwide
    6th most commonly diagnosed cancer

    830K

    Annual global deaths
    3rd leading cause of cancer death

    12.5%

    5 year survival rate in China
    18% 5 year survival rate in the U.S.

Explore more and Collaborate with us

bd@oricell.com
Thinkart